MetLife Investment Management’s Candel Therapeutics CADL Stock Holding History

MetLife Investment Management’s Portfolio CADL Stock Details CADL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$391K	Buy	37,970 +21,771	+134%	+$164K	﹤0.01%	2067
2026 Q1	$79.4K	Sell	16,199 -3,244	-17%	-$17.7K	﹤0.01%	2622
2025 Q4	$110K	Buy	19,443 +3,955	+26%	+$21.3K	﹤0.01%	2561
2025 Q3	$79K	Sell	15,488 -10,058	-39%	-$58.1K	﹤0.01%	2736
2025 Q2	$129K	Buy	25,546 +10,319	+68%	+$53.1K	﹤0.01%	2406
2025 Q1	$86K	Buy	15,227 +1,454	+11%	+$11.9K	﹤0.01%	2592
2024 Q4	$120K	Buy	13,773 +1,215	+10%	+$7.18K	﹤0.01%	2535
2024 Q3	$87K	Buy	+12,558	New	+$78K	﹤0.01%	2679

Other funds holding CADL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

MetLife Investment Management's CADL Position: Q2 2026 in Review

MetLife Investment Management increased its Candel Therapeutics (CADL) stake by 134% in Q2 2026, buying an estimated $164K and bringing the position to 37,970 shares worth $391K. The position accounts for ﹤0.01% of the portfolio, ranked #2067.

MetLife Investment Management first reported a position in CADL in Q3 2024 and has held it in 8 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

MetLife Investment Management held 37,970 shares of Candel Therapeutics worth $391K as of Q2 2026.
MetLife Investment Management bought 21,771 Candel Therapeutics shares in Q2 2026, an estimated $164K.
Candel Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2067 holding.
MetLife Investment Management first reported a position in Candel Therapeutics in Q3 2024 and has held it in 8 quarters since.
138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.